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Purpose: Our laboratory has developed methods required to covalently bind recombinant 
hirudin (rHir) to the surface of polyester vascular grafts. Using alkaline hydrolysis of 
the polyester surface, carboxyl-binding sites are created on the outer periphery of each 
fiber. A series of static, in vitro experiments have demonstrated that surface-bound rHir 
rapidly removes and inhibits activated human ~-thrombin from the reaction system; 
however, the performance of this modified graft material under physiologic flow condi- 
tions was undefined. 
Methods: An in vitro flow loop was used to evaluate structural stability of the 125I-rHir 
and lalI-albumin covalently bound to the surface of 6 mm interior diameter crimped 
polyester grafts exposed to either constant flow (n = 4; shear rate, 300 sec -1) or pulsatile 
flow (n = 4; maximum shear rate, 780 sec q)  conditions for a 7-day period. In a separate 
series of experiments, the kinetics of thrombin-rHir nteraction were evaluated through 
perfusion of 12SI-rHir-coated grafts (n = 6) with 131I-thrombin for a 27-hour period 
under constant flow conditions. Identically prepared 125I-albumin-coated grafts (n = 3) 
were used as controls. 
Results: Results of the stability experiments were independent of flow conditions, 
demonstrating moderate loss of both proteins, with rHir and albumin losses of 52.1% 
and 19.9% under constant flow and 49.1% and 21.6% under pulsatile flow, respectively. 
With results comparable with those of previous tatic experiments, rHir-coated grafts 
were significantly more effective at removing thrombin from the perfusion stream with 
laH-thrombin binding densities of 3.08 _+ 0.61 and 0.64 -+ 0.04 N IHU/cm 2 (p < 0.01) 
for rHir-coated and albumin-coated grafts, respectively. Estimates of the total amount 
of thrombin inactivated uring the perfusion period similarly demonstrated a marked 
difference between the rHir-coated and control graft segments (125 _+ 8 vs. 3 -+ 14 
NIHU; p < 0.005). 
Conclusions: These in vitro flow results illustrate that polyester grafts with covalently 
bound rHir can provide significant reductions in local thrombin concentration under 
physiologic flow conditions, and can serve as a foundation with which to understand the 
performance of these grafts when implanted in vivo trader physiologic flow and shear 
rates. (J Vasc Surg 1998;27:1117-27.) 
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Although advances in the field of biomaterials 
have yielded a progressive improvement in the qual- 
ity of vascular graft prostheses, the development of a 
small-diameter p osthetic graft that is resistant o 
initial thrombosis and secondary intimal hyperplasia 
remains elusive. Thrombin has a central role in the 
cleavage of fibrinogen, activation of platelets, and 
proliferation of smooth muscle cells; thus local inhi- 
bition of this agent within vascular grafts has been an 
attractive area of research. Among the strategies that 
have been used in an effort to achieve this goal has 
been the ionic attachment or covalent binding of  
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Fig. 1. Schematic diagram illustrates initial surface modi- 
fication of polyester graft viaalkaline hydrolysis with sub- 
sequent covalent linkage of albumin-SMCC and hirudin- 
SH complexes. 
specific antithrombin agents at the blood-biomater- 
ial interface. Heparin, the most extensively adminis- 
tered systemic antithrombin agent, has been the 
focus of a majority of these surface modification 
studies. 1-13 Polyurethanes, with or without spacer 
groups, in conjunction with covalently bonded 
heparin have been shown to reduce occlusion rates 
under low flow conditions in several ex vivo shunt 
models.l,2,7 Initial studies that examined the in vivo 
performance of these heparin-coated biomaterials 
reported that these conduits reduced surface throm- 
bus formation and decreased anastomotic hyperpla- 
sia in 16-week implantation studie.s.3, n Although 
these studies have formed the foundation for exten- 
sive clinical use of heparin-bonded tubing in extra- 
corporeal systems, a role for these materials in the 
long-term implantation required for arterial replace- 
ment or bypass urgery seems limited. 
In an effort to provide a clinically useful vascular 
graft with enhanced patency characteristics, our lab- 
oratory has developed the technology through 
which proteins can be covalently bonded to the sur- 
face of polyester fibers)4, is After alkaline hydrolysis 
of the polyester fibers and placement of an albumin 
base coat, the target protein is covalently attached to 
the graft surface. Recent studies have used the 
potent antithrombin agent hirudin as the target pro- 
tein of interest. 15 
Hirudin is a 6.97 kd protein that spccifcally and 
irreversibly binds to both the catalytic and fibrino- 
gen binding sites of activated thrombin,16,17 Al- 
though the chnical use of hirudin systemically has 
been limited because of an increased potential for 
spontaneous hemorrhage,18,19 animal experiments 
indicate that the use of hirudin via continuous infu- 
sion may significantly reduce the degree of intimal 
hyperplasia after angioplasty. 2° This finding has 
recently been confirmed where local delivery of 
hirudin from transfected endothelial and smooth 
muscle cells significantly reduced the degree of 
neointimal proliferation after arterial injury. 21 
Recent studies in our laboratory were undertak- 
en to optimize covalent linkage of recombinant 
hirudin (rHir) to a polyester surface, is Preliminary 
evaluation of this modified material used a batch, in 
vitro system in which rHir-coated graft segments 
were exposed to various concentrations of activated 
thrombin for defined periods up to 1 hour. These 
studies demonstrated the graft to remove and inhib- 
it thrombin in the surrounding static solution. 
Although the utility of this novel biomaterial ppears 
promising, the performance ofthis graft in a physio- 
logic flow environment was undefined, The current 
series of experiments were designed to evaluate this 
problem, namely to define the stability of surface- 
bound rHir and examine the thrombin-rHir nterac- 
tion in an in vitro perfusion system under physio- 
logic flow conditions. 
METHODS 
Graft preparation. Covalent linkage of the rHir 
to the polyester surface was performed as previously 
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described, is Briefly, carboxyl group attachment si es 
were created through alimited alkaline hydrolysis of 
the polyester fibers (Fig. 1). These sites served as 
binding regions for 1-ethyl- 3-(3-dimethylamino- 
propyl) carbodiimide hydrochloride (EDC) cross- 
linker attachment ofa bovine serum albumin (BSA) 
base coat, which had previously been reacted with 
the heterobifunctional crosslinker sulfosuccinimdyl 
4- (N-maleimidomethyl) cyclohexane- 1-carboxylate 
(SMCC). After modification of the rHir with 2- 
iminothiolane hydrochloride (Traut's reagent) to 
create reactive sulfhydryl groups, final rHir binding 
to the albumin via the SMCC crosslinker was 
accomplished. 
Woven 6.0 mm crimped Cooley Veri-soft poly- 
ester grafts (Dacron, Meadox Medicals, Inc., 
Oakland, N.J.) measuring 3.0 cm in length were 
weighed, washed in 100 ml scouring solution (14.5 
mmol/L Na2CO3, 1% v/v Tween 20) for 30 min- 
utes at 60 ° C, and rinsed in 200 ml distilled water 
(dH20) for 30 minutes at 60 ° C. Grafts then under- 
went a 30-minute alkaline hydrolysis in 0.5% NaOH 
followed by a second rinse in dH20 to terminate the 
reaction. Previous analysis of the hydrolyzed poly- 
ester material confirms the preservation of tensile 
strength and graft integrity. 14 
To trace the stability of the rHir (11.5 anti- 
thrombin units [ATU]/gg; Farmitalia, Milan, Italy) 
and BSA (Sigma Chemical, St. Louis) on the graft 
surface, proteins were iodinated with radioactive 
1251 and 131I, respectively. Two iodo-beads were 
incubated with 200 gCi 1251 or 13ii in 180 gl phos- 
phate buffered saline solution (PBS; 0.1 mol /L  
NaH2PO4, 0.05 mol/L NaCI, pH 7.4). rHir (1.0 
mg) or BSA (7.5 mg) was added and reacted for 12 
minutes. Free radioactive iodine was removed via 
elution through a PD-10 gel filtration column 
(Pharmacia, LKB, Piscataway, N.L) and concentrat- 
ed using a Microsep 3K concentrator (Filtron, 
Northborough, Mass.) at 3000 rpm for 3 hours. 
12SI-rHir and 131I-BSA were mixed with cold pro- 
tein to provide final hot:cold ratios of 20% and 50%, 
respectively. Trichloroacetic acid (TCA) precipita- 
tion demonstrated binding efficiencies of 70% to 
80% for 12SI-rHir and 97% to 99% for 131I-BSA. 
Graft segments were prepared for protein bind- 
ing via reaction with 6.0 ml of 10 mg/ml EDC for 
30 minutes at room temperature on an inversion 
mixer. Concurrently, SMCC crosslinker was reacted 
with 1311 in a 1:50 molar ratio at 37 ° C for 30 min- 
utes, followed by purification through a PD-10 col- 
umn. Final 131I-BSA-SMCC concentration was 
adjusted to 14.8 gmol/L. Graft segments were then 
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Fig. 2. Schematic reprcsentations of constant and pul- 
satile flow perfusion circuits used to evaluate rHir and BSA 
covalcnt bound surfaces. 
incubated in the 131I-BSA-SMCC solution for 2 
hours at room temperature onan inversion mixer. At 
completion, unbound protein was removed with 
four 5-minute sonications in 5 ml of 0.05% v/v 
Tween 20 in PBS. In preparation for binding, 1251- 
rHir was reacted with Traut's reagent i  a 1:2 molar 
ratio for 30 minutes at 37 ° C, followed by purifica- 
tion through aPD-10 column, with the final protein 
concentration adjusted to 5.0 txmol/L. Final bind- 
ing was then accomplished byincubation of the graft 
segments with the modified 125I-rHir overnight on 
an inversion mixer at 4 ° C. Unbound protein was 
again removed via four 5-minute sonications in 5 ml 
of 0.05% v/v Tween 20 in PBS. 
Per fus ion  systems. Two bench-top in vitro flow 
loops, which were fully instrumented to carefully 
monitor the flow environment (Fig. 2), were used in 
the current experiments: (1) a constant flow system 
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Fig. 3. Experimentally obtained pulsatile flow waveform 
and estimated pulsatile pressure gradient and shear rate 
through the Wormersley approximation for cyclic flow in 
a tube. 
that was initially used to measure thc protein surface 
stability, followed by a series of studies to evaluate 
the thrombin binding kinetics to the modified graft 
segments; and (2) a pulsatile flow system that was 
used to determine protein surface stability in a phys- 
iologic oscillating shear stress environment. 
The constant flow perfusion system uses a gravi- 
ty pressure head to provide steady flow from the per- 
fusate reservoir, through the heating coil, which was 
used to maintain perfusate flow at 37 ° C, to the graft 
segment. To prevent significant efflux of perfusate 
through the porous graft wall, the external surface of 
the graft was encased in a carefully fitted segment of 
inert tubing, thus maintaining flow in an axial direc- 
tion. Flow disturbances at the inlet and exit of the 
graft were minimized by the use of appropriately 
sized smooth-bore connectors. The flow environ- 
ment at the exit site of the graft was monitored with 
a strain gauge pressure catheter (Millar Instruments, 
Inc., Houston) and electromagnetic flowmeter 
(Carolina Medical Electronics, King, N.C.). Recir- 
culation of the perfusate in the system was main- 
tained through the peristaltic pump (Model 1215, 
Harvard Apparatus, Framingham, Mass.). A second 
fluid reservoir was used to isolate the test graft seg- 
ment from the significant pressure and flow oscilla- 
tions generated by the peristaltic pump. 
Flow and pressure waveforms within the pulsatile 
perfusion system were generated bya piston-driven 
blood pump (Model 1421, Harvard Apparatus) that 
drove perfusate from the reservoir through the 37 ° 
C heating coil to the test graft. Grafts were again 
placed within inert tubing segments to prevent per- 
fusate leakage through the wall. The compliance 
chamber was used to dampen the pressure waveform 
to physiologic levels, and the flowmeter and pressure 
catheter were again used to closely monitor the 
hemodynamics of the system. 
All experiments were conducted using a 5% 
BSA/PBS perfusate containing 200 unit/ml peni- 
cillin and 0.2 mg/ml streptomycin (Sigma Chemical) 
to prevent bacterial contamination. Priming volume 
of both perfusion systems was 400 ml. 
Hemodynamic simulations. In the constant 
flow experiments, grafts were perfused at a flow rate 
of 400 ml/min with a pressure of 100 mm Hg. 
Assuming the graft may be modeled as a semiinfinite 
rigid tube, calculation of the surface fluid shear via 
Poiseuille's law yielded a steady physiologic shear 
rate of 310 sec -1, a value consistent with the shear 
rates imposed on vascular grafts implanted in vivo. 
Assuming a perfusate viscosity equal to that of plas- 
ma (p = 0.13 dyne sec/cm2), this corresponded to a 
Reynolds number of 1120. 
During the pulsatile flow studies, grafts were 
exposed to a mean flow rate of 400 ml/min (with 
maximum and minimum flow rates of 1000 and -10 
ml/min, respectively) and a pulsatile pressure of 
120/80 mm Hg. Cyclic waveforms were generated 
at a frequency of 1 sec -1 while the systolic:diastolic 
ratio was maintained at 0.50. Estimation of the 
dynamic shear rate at the graft surface was accom- 
plished through the Wormersley approximation for 
cyclic flow in a semiinfinite rigid tube. 22 Briefly, to 
determine the shear rates, the velocity profile, v(r,t) 
was assumed to be of the form 
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where r equals radial coordinate, R equals graft 
radius, fequals pulse frequency, t equals time, and 
A o + A 1 sin 27rft equals the axial pressure gradient. 
The shear rate at the graft surface, %, was then 
directly obtained from the radial velocity gradient 
dv(r,t) _ R (A  ° + A1 sin 2nft) 
Tw = dr r=R 2g 
Estimation of the constants A o and A 1 was 
accomplished by assuming the dynamic flow wave- 
form, Q(t), takes the form 
Q( t) = B o + B 1 sin 27rft 
where the constants Bo and B 1 were determined to 
be 8.2 ml/sec and 8.3 ml/sec, respectively, through 
numerical regression against he experimental wave 
form displayed in Fig. 3. Integrating the velocity 
profile across the cross-sectional area of the graft and 
equating to the above expression for Q(t) yielded 
the following expressions for A o and A 1 
AO=~R4Bo A1 = x8-~R4B1 
and the time dependent shear ate at he wall 
4 B Yw = ~--~( o + B1 sin 2xft) 
In the surface protein stability experiments 
where R = 0.3 cm and f = 1 sec -1, the analysis 
returned a maximum and minimum graft shear rate 
of 780 sec -1 and -5 sec -1, respectively. The time- 
dependent estimates for the wall shear ate across the 
cardiac ycle are provided in Fig. 3. 
Surface hirudin and albumin stability experi- 
ments. In preparation to evaluate the ability ofrHir  
and BSA to maintain their covalcnt linkage to the 
polyester surface in a flow environment, grafts were 
prepared with 125I-rHir and lSlI-BSA as detailed 
above. Two separate series of experiments were per- 
formed: (1) grafts were placed in a constant-flow, 
constant-pressure environment to assess urface pro- 
tein stability in a time-invariant flow field; and (2) 
grafts were placed in a pulsatile-flow, pulsatile-pres- 
sure environment to evaluate the effect of physio- 
logic, time-dependent oscillatory shear stress on the 
surface protein coatings. Grafts were individually 
assayed for 12~I and 131I activity in a Beckxnan y- 
counter approximately every 12 hours during the 7- 
day perfusion experiment. Data were expressed as 
the fractional loss of rHir and BSA from the surface. 
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Fig. 4. Time-dependent profiles of 125I-rHir and 1311- 
BSA loss from the polyester graft surface exposed to either 
a constant (upper) or pulsatile (lower) flow environment 
over a 7-day period. 
Four test graft segments were perfused under each 
experimental flow condition. 
Thrombin-hirudin interaction experiments. 
Whereas our previous research as demonstrated 
that the rHir-coated polyester graft material rapidly 
removes activated thrombin from solution, the abil- 
ity of the graft to do this in a physiologic flow envi- 
ronment remained undefined. A series of experi- 
ments were undertaken to quantify the kinetics of 
the thrombin-rHir interaction in a precise, con- 
trolled, constant flow environment. 
Human ~-thrombin (thrombin) and its interac- 
tions with the rHir-coated grafts were evaluated 
through use of a 1311 tracer. Two hundred NIH 
units (NIHU) of thrombin (3.054 NIHU/~tg; 
Enzyme Research Laboratories, South Bend, Ind.) 
were labeled with 200 ~tCi of 131I using the iodina- 
tion and purification techniques described above. 
Labeled thrombin tracer was combined with 200 
N IHU of unlabeled thrombin to provide a 50% 
hot:cold ratio for each perfusion experiment. TCA 
precipitation demonstrated a binding efficiency 
ranging from 75% to 80%. Previous experience in our 
laboratory has uncovered that approximately 20% to 
35% of the 131I-thrombin becomes biologically inac- 
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Table I. 125I-rHir or 131I-BSA loss from graft surface, 131I-thrombin binding to graft, and 1311 
inactivation in perfusatc 
125I-rHir grafts (n = 6) 125I-BSA grafts (n = 3) 
Graft weight (mg) 
Initial 125I-rHir concentration (ATU/cm 2) 
Final 12SI-rHir concentration (ATU/cm 2) 
Initial 12SI-BSA concentration (Ixg/cm 2) 
Final 12SI-BSA concentration (gg/cm 2) 
Percent 125I-rHir or 125I-BSA loss from surface 
lsl I -Thrombin bound to graft (N IHU/cm 2) 
131I-Thrombin bound to graft (NIHU) 
131I-Thrombin inactivation in perfusate (NIHU) 
200.0 ± 6.3 188.8 ± 7.2 
38.2 ± 1.8 
28.7 ± 4.7 
- -  7.4 +- 0.9 
- -  7.2 +- 0.7 
36.4% ± 5.4% 1.9% ± 2.4% 
3.08 ± 0.61 0.64 + 0.04 
23.8 + 2.6 3.9 -+ 0.3 
125 ± 8 3 ± 14 
p < 0.01 
p < 0.01 
p < 0.001 
p < 0.005 
Values are mean ± SEM. 
five as a result of the iodination processing. To deter- 
mine this quantity for each experiment, he biologic 
activity of the iodinated thrombin preparation was 
compared against a thrombin standard of known 
activity using the S-2238 chromogenic substrate 
assay (Chromagenix AB, Molndal, Sweden). This, in 
combination with a Lowry assay to determine the 
thrombin protein concentration, was used to accu- 
rately determine the 131I-thrombin-specific activity. 
Test graft segments with a 6 mm internal diame- 
ter and 3 cm length were prepared as detailed above, 
with one modification. With use of the 131I-throm- 
bin tracer in these experiments, grafts were only 
singly labeled with 12H-rHir, whereas the BSA base 
coat was not radiolabeled. To isolate the specific 
effect of surface-bound rHir in these perfusion stud- 
ies, a series of control grafts were prepared in which 
the polyester was coated with 125I-BSA, with omis- 
sion of the rHir. 
Twenty-seven hour perfusion experiments were 
individually performed for each test and control 
graft segment using the constant flow perfusion sys- 
tem described above. Grafts were perfused with 400 
ml of a 5% BSA/PBS/penicillin-streptomycin solu- 
tion containing 131I-thrombin, ranging from 0.5 to 
0.8 N IHU/ml  perfusate, at a constant flow rate of 
400 ml/min and intraluminal pressure of 100 mm 
Hg. Perfusate samples were collected throughout 
the perfusion period and were assayed for their 
remaining activated and total thrombin concentra- 
tions via the S-2238 chromogenic substrate assay 
(1.0 ml of 100 ~tmol/L S-2238 added to 0.5 ml 
sample) and y-counting, respectively. 131I-thrombin 
binding to the graft and 125I-rHir or 125I-BSA loss 
from the graft were determined through periodic 
removal of the grafts from the perfusion system for 
y-counting. The resulting data were used to deter- 
mine the fractional oss of 125I-rHir or 125I-BSA 
from the graft surface and the binding and inactiva- 
tion of 131I-thrombin. Differences were assessed 
using an unpaired, two-tailed Student's t test. 
Profiles of file 131I-thrombin binding and inactiva- 
tion throughout the perfusion period were also pre- 
pared to assess the thrombin-rHir interaction kinet- 
ics. After completion of this experiment, he unifor- 
mity of 125I-rHir coating and 131I-thrombin 
attachment along the graft length was assessed. 
Grafts were divided into eight equal segments, and 
each segment was individually assayed for 125I and 
131I activity. 
RESULTS 
Surface hirudin and albumin stability experi- 
ments. Four 3.0-cm length graft segments labeled 
with 125I-rHir and 131I-BSA were perfused for 7 
days in each of the constant flow and pulsatile flow 
systems as described above. Profiles illustrating the 
fractional loss ofradiolabeled proteins from the graft 
surface throughout the 7-day period arc provided 
for each flow environment (Fig. 4). Data points rep- 
resent he mean value for the given time period with 
error bars illustrating the standard error of the mean. 
Both profiles demonstrated consistent similarities, 
with time-dependent variability that appeared inde- 
pendent of the flow system. During the perfusion 
period from 0 to 3 days, gradual oss of both 12sI- 
rHir and 131I-BSA from the graft surface was 
observed, reaching approximately 10% to 15% for 
rHir and 4% to 6% for BSA by the third day. After 
this time period, a notable increase in the rate of 
protein removal was encountered, with a fivefold 
elevation in the rate ofrHir loss and threefold eleva- 
tion in BSA loss, such that the total protein loss 
reached 40% and 15% for rHir and BSA, respective- 
ly, by the fourth day. From days 5 to 7, the rate of 
protein detachment more closely approximated that 
seen through the first several days of the perfusion. 
By day 7, total 125I-rHir loss reached 52.1% - 0.4% 
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in the constant flow environment and 49.1% _+ 0.2% 
in the pulsatile flow environment. With a mean ini- 
tial 12aI-rHir density of 60.5 ATU/cm 2 for grafts 
placed in the constant flow system and 51.8 
ATU/cm 2 for pulsatile flow grafts, 29.0 and 26.4 
ATU/cm 2 remained covalently attached to the flow 
surfaces, respectively. 
Thrombin -h i rud in  interact ion experiments. 
Six test graft segments labeled with 125I-rHir and 
three control graft segments labeled with 125I-BSA, 
each measuring 3.0 cm in length, were prepared. 
Grafts were individually perfused for a 27-hour peri- 
od in a constant flow environment. The resultant 
125I-rHir or 125I-BSA surface densities and 13~I- 
thrombin graft binding and perfusate inactivation 
are listed in Table I. A significant difference between 
the fractional protein loss from the rHir test versus 
BSA control graft segments was obtained, with a 
125I-rHir loss of 36.4% _ 5.4% and a 125I-BSA loss 
of 1.9% ± 2.4% (p< 0.01). 
Comparable with our previous tatic experimen- 
tal results, the graft segments with rHir covalently 
bound were significantly more effective at removing 
and inhibiting thrombin from the perfusate than 
grafts with only covalently bound BSA. This is illus- 
trated by the clear difference in the density of 131I- 
thrombin bound (3.08 + 0.61 vs. 0.64 ± 0.04 
N IHU/cm2;  p < 0.01) and total 131I-thrombin 
bound (23.8 _+ 2.6 vs. 3.9 _+ 0.3 NIHU; p < 0.00i) 
to the rHir and BSA grafts, respectively. The effect 
of the rHir on the graft is also illustrated by the loss 
ofthrombin activity in the perfusate, as measured by 
the S-2238 chromogenic substrate assay. These data, 
used to calculate the 131I-thrombin i activation in 
the perfusate, demonstrated a marked difference 
between the rHir-coated and BSA-coated graft seg- 
ments (125 ± 8 vs. 3 ± 14 NIHU; p < 0.005). 
Inherent in these types of in vitro ldnetic flow 
studies is the potential artifact induced by nonspe- 
cific binding of the 131I-thrombin tracer to the tub- 
ing and other components of the flow system. To 
evaluate the effect of  this nonspecific binding, a 
series of experiments were performed in which i31I- 
thrombin was introduced into the flow system and 
perfused for 27 hours without a graft segment (data 
not shown). Analysis of these results demonstrated 
the nonspecific binding to consistently range from 
12% to 18% of thc initial 131I-thrombin concentra- 
tion, correlating to nonspecific adhcrence of 35 to 
50 N IHU ofthrombin to the system. 
Time-dependent profiles of 131I-thrombin bind- 
ing to perfused grafts and 13]I-thrombin i activation 
in the perfusate during the 27-hour flow study are 
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Fig. 5. Time-dependent profiles of 13]I-thrombin bind- 
ing to rHir-coated and BSA-coated graft segments 
(upper). Time-dependent profiles of circulating thrombin 
inactivation in perfusate, as determined by S-2238 chro- 
mogenic substrate assay, for rHir-eoated and BSA-coated 
graft segments (lower). Grafts were perfused under con- 
stant flow conditions for a 27-hour period. 
illustrated in Fig. 5. Data points and error bars rep- 
resent he mean and standard error of the mean for 
each time period. These curves are in agreement with 
above findings, namely that both thrombin binding 
and inactivation were significantly enhanced by link- 
age of rHir to the polyester surface. The apparent 
nonlinear trend of the binding and inactivation pro- 
files was apparent, both demonstrating a more rapid 
early rate, which was reduced later in the experiment. 
Graft specimens were divided axially into 0.5 cm 
length segments to assess the distribution of the 
125I-rHir coating and 131I-thrombin binding on the 
graft surface after 27 hours. The surface density of 
rHir demonstrated little variability along the graft 
length (range, 23.2 to 25.8 ATU/cm2), suggesting 
uniformity in both the initial graft preparation as 
well as the surface fluid shearing forces. The absence 
of a disturbed flow entrance or exit region to the 
graft is similarly supported by the near constant 
uptake of ]31I-thrombin along the graft (range, 2.4 
to 2.7 NIHU/cm2),  indicating a uniform diffusion 
boundary layer regulating transport of thrombin to 
the surface. 
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DISCUSSION 
Significant research has been devoted to the 
development of a blood-contacting biomaterial that 
is resistant to thrombus formation. Investigation of 
heparin-coated biopolymers have demonstrated a 
reduction in both the acute thrombosisL2,7 aswell as 
the secondary intimal hyperplasia of small diameter 
grafts. 11 However, development of these polyethyl- 
ene-based, heparin-bonded products has failed to 
result in a clinically useful vascular prosthesis. The 
current experiment used a covalent binding process 
to polyester fibers in an effort to achieve this goal. 
Initial studies by other investigators has suggest- 
cd that rHir applied either systemically 2° or locally 21 
is effective in reducing both acute graft thrombosis 
as well as secondary intimal hyperplasia, whereas 
preliminary work in our laboratory has verified that 
the potent antithrombotic activity of rHir is main- 
tained after covalent attachment to either soluble 23 
or surface-bound proteins, is Based on these obser- 
vations and early experiments, further analysis of 
rHir-coated polyester grafts was undertaken. 
Initial studies in the current series of experiments 
focused on evaluating the stability of the surface- 
bound rHir and BSA coatings under both constant 
and oscillatory shearing forces over a 7-day period. 
Examination of the disassociation profiles demon- 
strated striking similarities between the two flow 
simulations (Fig. 4). Although no similar studies 
that examined the effect ofpulsatilc flow on protein- 
coated surfaces were available for comparison, it is 
interesting to note that the 2.5-fold elevation in 
peak shear ate present in the oscillatory flow system 
(780 vs 310 sec -1) yielded no significant augmenta- 
tion in the rate of protein loss from the graft surface. 
Examination of the time course for surface pro- 
tein loss is also of interest, with both profiles show- 
ing a relatively slow rate of rHir and BSA loss over 
the first 3 days. This was followed by a more rapid 
rate of removal between days 3 and 4, leading to a 
notable reduction in this rate by days 5 to 7. These 
findings were in contrast o the performance of 
rHir-coated and BSA-coated grafts maintained in a 
no-flow environment, where no significant surface 
loss of protein was observed for up to a 2-week peri- 
od (data not shown). Although the mechanisms 
underlying this pattern are unclear, it is interesting 
to speculate that this enhancement between days 3 
and 4 followed by the subsequent decline in surface 
protein loss may, in part, be explained by the delayed 
release of noncovalently bound rHir and BSA. These 
proteins which were wcaldy associated with the poly- 
ester fibers may become dislodged through pro- 
longed exposure to fluid shearing forces. Later 
reduction in the rate of protein loss could then occur 
through depletion of the noncovalenfly bound pro- 
tein pool within the graft wall. Also playing a part in 
this characteristic protein elution pattern may be a 
nonuniform loss of rHir and BSA from the graft 
matrix. The exposure of the graft to an isolated axial 
perfusate flow yielded fluid shearing forces that were 
maximum at the luminal surface, reducing rapidly 
with progression into the graft wall. This nonuni- 
form exposure of the graft to the imposed shear may 
have resulted in an accelerated rate of protein loss 
along the luminal surface, with the reduction in the 
total rate of protein loss observed later in the perfu- 
sion, again a result of local depletion of surface 
protein. 
The rHir loss was evaluated not only in the 7-day 
coating stability experiments but also in the 27-hour 
thrombin-rHir interaction experiments, with signifi- 
cantly different findings. Although an approximate 
8% loss of rHir from the graft surface was noted in 
the first 27 hours of the constant-flow stability 
experiment (Fig. 4), the addition of activated 
thrombin to the perfusion system resulted in an 
increase in rHir removal to 36.4% (Table I). This is 
in contrast to the loss of BSA from the surface, 
which was relatively similar in both the presence and 
absence of thrombin (4.1% vs 1.9%, respectively). 
Although the mechanism for this enhanced removal 
of rHir is speculative, most probable is an increased 
propensity for dissociation of rHir from the graft 
surface after thrombin binding. Structural analysis of 
the thrombin-rHir interaction has demonstrated 
multiple conformational changes that are induced by 
rHir binding to the thrombin exosite. These spatial 
changes may reduce the stability of the sulfur bond 
between the rHir and SMCC crosslinker, resulting 
in an enhanced rate of rHir release from the surface. 
In addition, the reduced stability of the rHir on the 
graft surface may be related to an increased fluid 
induced drag force associated with thrombin bind- 
ing. Interaction of thrombin with surface-bound 
rHir results in an increase in mass of the attached 
protein from 6.9 kd to 43.5 kd, corresponding to an 
approximate 3.4-fold increase in both the projected 
surface area and fluid drag forces on the protein 
complex. 24 This estimate may provide some insight 
in relation to the fourfold increase in rHir loss 
induced by the addition of thrombin. 
An understanding of the potential in vivo perfor- 
mance of the rHir-coated graft may be obtained 
from examination of the thrombin-rHir interaction 
experiments (Fig. 6). Throughout he 27-hour per- 
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Fig. 6. Schematic representation illustrates group-averaged results of rHir bound polyester 
grafts perfused with thrombin over a 27-hour period. 
fusion period, exposure of the rHir graft segment to 
a perfusate thrombin concentration of 0.7 
N IHU/ml  (or 255 NIHU total thrombin) resulted 
in a 49% inactivation ofthrombin (125 NIHU inac- 
tivated thrombin), as determined by the S-2238 
chromogenic substratc assay. Combining these find- 
ings with the data collected from 131I-thrombin 
binding and 125I-rHir loss at the graft surface, 30% 
of the initial applied thrombin (or 78 NIHU) was 
found to be bound to rHir. Associated with throm- 
bin binding to the rHir, there was an enhanced 
release of the thrombin-rHir complex, resulting in a 
69% loss of the complex into the perfusate (with 24 
NIHU thrombin bound to the graft surface and 54 
NIHU of a thrombin-rHir complex free in solution 
at the end of the experiment). The remaining 47 
NIHU of thrombin inactivation resulted from non- 
specific binding of activated thrombin to compo- 
nents of the flow system. 
Examination of the time-dependent profiles for 
thrombin binding to the graft and inactivation i  the 
perfusate (Fig. 5) support he above findings, name- 
ly that rHir-coated grafts, in comparison with BSA- 
coated controls, effectively bind and remove activat- 
ed thrombin from the reaction solution in a physio- 
logic flow environment. Notably, these profiles 
displayed a nonlinear pattern of binding and inacti- 
vation, evidenced by the rapid initial removal of 
thrombin followed by a reduction in this rate later in 
the perfusion period. Although the exact etiologic 
mechanism underlying this pattern was unclear, sev- 
erN potential mechanisms may have played a role. 
With previous investigators having documented the 
rapid absorption of circulating proteins on polyester 
graft material, 2~ passivation of the graft fibers with 
BSA may have decreased the available rHir binding 
sites on the surface, leading to a gradual decline in 
the rate of thrombin uptake by the graft. In addi- 
tion, the reduction in available rHir binding sites 
throughout the experiment may have been related 
to either depletion of surface rHir sites, with only 
less-accessible sites within the graft matrix available 
for binding, or loss of total rHir sites, after contin- 
ued loss of thrombin-rHir complex into the per- 
fusate. Although the current experiments cannot 
clearly isolate the contribution of each of these 
mechanisms, an understanding of their roles will 
have significant implications in the function of these 
grafts long term within an in vivo environment. 
Although it provides a fundamental understand- 
ing of the interaction between thrombin and sur- 
face-bound rHir in a flow stream, the current model 
possessed several limitations. With the substitution 
of a buffered albumin perfusate for whole blood, the 
influence of red blood cells and platelets on throm- 
bin transport and binding was omitted. Although 
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these omissions will likely induce some deviation 
from in vivo function, the use of an albumin per- 
fusate was instrumental in providing a system in 
which changes in circulating thrombin concentra- 
tion could be accurately assessed. As such, the cur- 
rent analysis provided a first-order approximation of 
the thrombin binding kinetics to the graft surface. 
Also omitted in the current binding experiments was 
the effect of pulsatile pressure and flow. Although 
the overall influence of these nonlinear flow dynam- 
ics on graft function is speculative, the anticipated 
reduction in the surface boundary layer will lead to 
enhanced transport of thrombin to the graft and 
more rapid binding to the rHir. Although these fac- 
tors will influence ultimate graft function, the com- 
plexities induced by their inclusion were reserved for 
later in vivo experimentation. 
The utility of this modified graft material in vivo 
will be dependent on the stability and longevity of 
the rHir coating. When all available rHir binding 
sites become bound to thrombin, the antithrom- 
boric properties of the graft will be lost. The cur- 
rent experimental findings were used to provide an 
estimate of the duration of graft function. Although 
the graft was exposed to a fixed load of thrombin 
throughout the per fusion period, the initial rate of 
thrombin uptake provided a method with which to 
base these calculations. Assuming the thrombin- 
rHir surface binding was predicted by a first-order 
rate expression with a constant hrombin concen- 
tration of 0.7 N IHU/ml ,  a first-order rate constant 
of 0.7 ml/hr  cm 2 for the binding reaction was 
obtained. Although the extent of thrombin activa- 
tion and subsequent local thrombin concentrations 
that occur within implanted prosthetic vascular 
grafts have not clearly been defined, several investi- 
gators have estimated that a thrombin concentra- 
tion ranging from 0.1 to 1.0 N IHU/ml  is required 
for platelet aggregation and the initiation of throm- 
bus formation. 26-28 Using these estimates for the 
local thrombin concentration, an approximate rHir 
graft surface density of 40 ATU/cm 2 and the above 
value for the first-order ate constant, the life span 
of the rHir coating in an in vivo environment was 
estimated to range from 7.8 to 78 days. Also influ- 
encing the early effectiveness and overall duration 
of graft function will be the rate at which surface 
passivation occurs. This deposition of circulating 
proteins and formed blood elements will clearly 
lead to a reduction in available rHir binding sites 
and further diminish the estimated life span of the 
rHir coating. 
CONCLUSION 
The current series of experiments provided an 
initial performance evaluation ofa rHir/BSA-coated 
polyester vascular prosthesis. Coating stability was 
examined in both a constant and pulsatile flow envi- 
ronment and demonstrated moderate loss of both 
proteins, with the type of flow not significantly alter- 
ing these findings. Addition of thrombin to the flow 
system significantly increased the rate of rHir loss 
from the graft, which is likely related to removal of 
thrombin-rHir complex from the surface. The kinet- 
ics of the thrombin-rHir interaction demonstrated 
the covalenfly bound rHir graft segments to effec- 
tively remove and inhibit thrombin from solution, 
significantly reducing the biologically active proco- 
agulant in the perfusate stream. With this infor- 
mation, studies investigating the impact of this 
reduction in local thrombin concentration on the 
pathologic processes of thrombosis and intimal 
hyperplasia may be undertaken. 
The authors would like to thank Meadox Medicals, Inc., 
for donation of the graft materials used in these studies. 
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D ISCUSSION 
Dr. Rober t  B. Patterson (Providence, R.I.). I have 
two questions regarding your experimental design. First, 
have you characterized the surface of your graft with elec- 
tron spectography for chemical analysis or other methods 
to establish that indeed you have active hydroxyl groups 
for covalent attachment? We have found the modification 
of a graft surface to be quite a daunting procedure and the 
difference between covalent attachment and absorption to 
be a critical one. 
In a similar vein, have you considered an open system 
rather than a closed system? In your pump system, you 
had a constant concentrat ion of thrombin,  and the 
results could be affected by a steady-state adsorption and 
deadsorption, 
Dr. Scott A. Berceli. I will address the second question 
first. We have used only a closed system in our experi- 
ments. However, because the increased binding to the 
graft was seen in only the hirudin-bound group, I suggest 
that this is more than just surface adsorption. 
As to first question, in terms of evaluation of the 
hydroxyl groups, we have not as yet fully performed a 
detailed surface analysis. 
